Evidence map›Paper›PMID 31009338›Full record

ArticleMonoclonal antibodies in immunodiagnosis and immunotherapy2019

CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program.

Thilipan Thaventhiran, Wai Wong, Ahmad F Alghanem, Naif Alhumeed, Mohammad A Aljasir, Simeon Ramsey, Swaminathan Sethu, Han Xian Aw Yeang, Amy E Chadwick, Michael Cross and 5 more

Abstract read
In one paragraph

Article in Monoclonal antibodies in immunodiagnosis and immunotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Bio-protocol · 2021
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Thilipan Thaventhiran1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
Wai Wong1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
Ahmad F Alghanem1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
Naif Alhumeed1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
Mohammad A Aljasir1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
Simeon Ramsey2 Inflammation and Remodeling, Pfizer Research Unit, Cambridge, Massachusetts.
Swaminathan Sethu1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
Han Xian Aw Yeang1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
Amy E Chadwick1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
Michael Cross1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
Steven D Webb1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
Laiche Djouhri3 Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Christina Ball4 National Institute for Biological Standards and Control, Hertfordshire, United Kingdom.
Richard Stebbings4 National Institute for Biological Standards and Control, Hertfordshire, United Kingdom.
Jean G Sathish1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.

Funding

Medical Research Council MR/L006758/1
6 · The paper itself

Abstract

CD28 superagonist (CD28SA), a therapeutic immunomodulatory monoclonal antibody triggered rapid and exaggerated activation of CD4

Indexed as

Acetyl Coenzyme AAntibodies, MonoclonalCD28 AntigensCD4-Positive T-LymphocytesCell ProliferationGlucoseGlycolysisHumansImmunologic MemoryLipogenesisLymphocyte ActivationNeoplasmsProtein KinasesT-Lymphocytes, RegulatoryTumor Cells, CulturedAcetyl Coenzyme AAntibodies, MonoclonalATP-citrate lyase kinaseCD28 AntigensGlucoseProtein KinasesCD28 superagonistCD4 effector memory T cellsglycolysislipogenesisoxidative phosphorylation

Identifiers

PMID31009338
PMCPMC6634261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.